Abbvie and Genentech to Launch Officially on TrumpRx Platform
Pharmaceutical giants Abbvie and Genentech are set to officially begin selling their medications on the discounted pharmaceutical platform, TrumpRx, starting this Monday. This move marks a significant step in providing affordable healthcare options for patients.
Details about Abbvie’s Offerings
Abbvie will introduce its well-known medication, Humira, on the TrumpRx platform. This drug is primarily used for treating conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- Discount Rate: Patients will see an impressive 86% discount on Humira.
- Previous Price: Uninsured individuals previously faced costs exceeding $6,900.
- New Price: The TrumpRx platform will offer Humira for only $950.
Genentech’s Contribution
Genentech will also contribute to the TrumpRx offerings with its antiviral medication, Xofluza. This single-dose pill is used for treating and preventing the flu.
- Originally Priced At: Xofluza was previously available at $168.
- New Price After Negotiation: Patients can now access it for approximately $50.
Eligibility and Additional Information
The discounted prescriptions on TrumpRx are designed for uninsured individuals or those whose insurance plans do not cover these specific medications. Those who have insurance generally receive lower out-of-pocket prices.
Future Plans for TrumpRx
A White House official indicated that there are efforts underway to formalize these discount prescription deals as part of the “Great Healthcare Plan.” This would allow individuals on government insurance to utilize copays for medications bought through TrumpRx, although Congress has not yet addressed this initiative.
Expanded Offerings and Impact
In addition to Abbvie and Genentech, Amgen will expand its offerings on the TrumpRx platform. This includes arthritis medication Enbrel and psoriasis medication Otezla. Overall, TrumpRx will feature over 61 medications at reduced prices, a significant increase from the initial 40 available when the platform was launched in February.
Through initiatives like the TrumpRx platform, the administration aims to alleviate the burden of high prescription drug prices by employing agreements that ensure U.S. consumers pay the same prices as those in other countries.
